Life Sciences 2014-10-22

Evidence for the involvement of descending pain-inhibitory mechanisms in the attenuation of cancer pain by carvacrol aided through a docking study.

Adriana G Guimarães, Luciana Scotti, Marcus Tullius Scotti, Francisco J B Mendonça Júnior, Nayara S R Melo, Rafael S Alves, Waldecy De Lucca Júnior, Daniel P Bezerra, Daniel P Gelain, Lucindo J Quintans Júnior

Index: Life Sci. 116(1) , 8-15, (2014)

Full Text: HTML

Abstract

The present study evaluated the carvacrol (CARV) effect on hyperalgesia and nociception induced by sarcoma 180 (S180) in mice.Carvacrol treatment (12.5-50mg/kgs.c.) once daily for 15days was started 24h after injection of the sarcoma cells in the hind paw (s.c.). Mice were evaluated for mechanical sensitivity (von Frey), spontaneous and palpation-induced nociception, limb use and tumor growth on alternate days. CARV effects on the central nervous system were evaluated through immunofluorescence for Fos protein. Molecular docking studies also were performed to evaluate intermolecular interactions of the carvacrol and muscimol, as ligands of interleukin-10 and GABAA receptors.CARV was able to significantly reduce mechanical hyperalgesia and spontaneous and palpation-induced nociception, improve use paw, decrease the number of positively marked neurons in lumbar spinal cord and activate periaqueductal gray, nucleus raphe magnus and locus coeruleus. CARV also caused significant decreased tumor growth. Docking studies showed favorable interaction overlay of the CARV with IL-10 and GABAA.Together, these results demonstrated that CARV may be an interesting option for the development of new analgesic drugs for the management of cancer pain.Copyright © 2014 Elsevier Inc. All rights reserved.